Healthcare

ImpediMed Limited (ASX:IPD)

Industry Group : Health Care Equipment & Services | Industry Group Name : Health Care Equipment & Supplies

Market Price : AUD 0.170 (0%)

(as on 2021-10-23 03:55:44)

Market Cap : AUD 254.507 M

Previous Close Open Close* Day Range 52 WEEK HIGH LOW
0.17 0.165 0.17 0.165L 0.175 H 0.078L 0.19 H
Last Trade 0.17
Change% 0.0000
52 W H/L 0.19/0.078
EBITDA -21.373 M
NPAT After Abnormal Items -20.706 M
Equity 25.514 M
ROE% -81.16%
Total Liabilities 8.691 M
Total Revenue 10.79 M
Cash and Cash Equivalents 19.681 M

Stock Information

Share price 0.17
Market Cap 254.507 M
Price/Gross Cash Flow -12.29
Dividend Yield Excluding Special 0.00%
Ending Shares 1.492 B
52-Week Range 0.078-0.19
P/E ratio 0.000
Sector P/E --
EPS -1.72
EV/EBITDA --
Net Profit Margin (%) -247.89%
Gross Cash Flows Per Share -0.01
Net Gearing -75.28%
Gross DPS (AUD) 0
Gross Dividend Yield (Annualized) 0.00%
Earnings Yield 0.000
Net Tangible Asset (NTA) 0.01
Sales Per Share 0.01
Book Value Per Share 0.02

Announcements

Heading Date/Time
Change in substantial holding  21/10/2021 4:42PM
Investor Presentation  21/10/2021 8:18AM
PREVENT Trial Successful, Statistically Significant Results  19/10/2021 11:02AM
ImpediMed Investor Conference Call Notification  19/10/2021 10:18AM
Trading Halt  19/10/2021 8:47AM
Supplementary Information-Advocate HF Program and Icon Group  13/10/2021 11:26AM
Change of Director's Interest Notice - Mr Donald Williams  08/10/2021 3:56PM
Change of Director's Interest Notice - Mr Scott Ward  08/10/2021 3:54PM
Change of Director's Interest Notice - Mr Amit Patel  08/10/2021 3:49PM
Change of Director's Interest Notice - Dr Robert Graham  08/10/2021 3:48PM
Change of Director's Interest Notice - Ms Judith Downes  08/10/2021 3:47PM
Change of Director's Interest Notice - Mr Richard Carreon  08/10/2021 3:46PM
Change of Director's Interest Notice - Mr David Anderson  08/10/2021 3:45PM
Notification of cessation of securities - IPD  07/10/2021 11:16AM
Online Meeting Guide  07/10/2021 10:11AM
Notice of Annual General Meeting/Proxy Form  07/10/2021 9:45AM
Retirement of Chairman  07/10/2021 9:44AM
Application for quotation of securities - IPD  06/10/2021 12:46PM
Notice under Section 708A(5)(e) of the Corporations Act  06/10/2021 12:41PM
New Corporate Oncology Account with Icon Group  30/09/2021 8:16AM
SOZO Heart Failure Program Initiated at AdvocateAuroraHealth  27/09/2021 8:21AM
HFSA Abstracts Demonstrate Utility of SOZO for HF Patients  13/09/2021 8:20AM
Notice under Section 708A(5)(e) of the Corporations Act  31/08/2021 2:29PM
Application for quotation of securities - IPD  31/08/2021 2:27PM
Appendix 4G and Corporate Governance Statement  25/08/2021 8:12AM
Annual Report 30 June 2021  25/08/2021 8:11AM
Appendix 4E  25/08/2021 8:09AM
Receipt of $1.8 Million R&D Tax Incentive Refund  24/08/2021 10:46AM
FDA Grants Breakthrough Device Designation for Renal Failure  23/08/2021 8:18AM

Similar Companies

Related Articles

About Company

A global company, ImpediMed Limited (ASX:IPD) is a world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies. These are used in the noninvasive clinical assessment and monitoring of fluid status and tissue composition.

ImpediMed was founded and is headquartered in Brisbane, Australia. Operation run in the United States and Europe.

The Company’s devices accurately and noninvasively measure a patient’s total body water, and extracellular and intracellular fluid volumes to aid in the assessment and interventions for chronic diseases.

ImpediMed, along with its subsidiaries have pioneered the use of BIS technology. The first commercially available BIS device was produced in 1990.

Notably, the Company’s L-Dex® device was the first FDA-cleared medical technology to use BIS for the assessment of lymphedema. Currently, the use of L-Dex is now recommended in clinical practice guidelines of research centers and professional organizations across the country.

In 2017, ImpediMed launched SOZO®, the world’s most advanced BIS device. It is an FDA-cleared, CE-marked and ARTG-listed digital health platform. SOZO® helps in the early detection of secondary lymphedema, offers fluid status for patients living with heart failure and enables measurement and tracking of various body composition parameters.

A single, powerful SOZO® reading allows clinicians across multiple specialties to provide individualized, proactive care that can help improve patient outcomes.

The Company is exploring the use of its advanced bioimpedance technology for a wide range of commercial applications such as General health and weight management, bone content and protein-calorie malnutrition.

Corporate Information

company address Unit 1, 50 Parker Court, PINKENBA, QLD, AUSTRALIA, 4008

company phone(07) 3860 3700

company websitehttp://www.impedimed.com

Dividends

Ex-Dividend Date Franking DPS (AUD) Dividend Yield
30/06/2021 -- 0.000 0.00%
30/06/2020 -- 0.000 0.00%
30/06/2019 -- 0.000 0.00%
30/06/2018 -- 0.000 0.00%
30/06/2017 -- 0.000 0.00%
30/06/2016 -- 0.000 0.00%
30/06/2015 -- 0.000 0.00%
30/06/2014 -- 0.000 0.00%
30/06/2013 -- 0.000 0.00%
30/06/2012 -- 0.000 0.00%

Event Calendar

Event Type Event Date Event Year
Report (Annual) 2022-08-24 2022
Report (Prelim) 2022-08-24 2022
Report (Interim) 2022-02-21 2022

Financials

Breakdown 30/06/2021 30/06/2020 30/06/2019 30/06/2018 30/06/2017
Trading Revenue 8.353 M 5.694 M 4.098 M 4.797 M 5.766 M
Other Revenue 2.437 M 4.189 M 2.702 M 3.078 M 2.882 M
Total Revenue 10.79 M 9.883 M 6.8 M 7.875 M 8.648 M
Interest Income 21,000 39,000 371,000 428,000 367,000
Interest Expenses -52,000 0 0 0 0
Expenses -29.726 M -29.815 M -30.901 M -34.975 M -36.274 M
EBITDA -18.936 M -19.932 M -24.101 M -27.1 M -27.626 M
Depreciation and Amortization -1.7 M -1.436 M -682,000 -460,000 -272,000
Depreciation -400,000 -461,000 -222,000 -353,000 -259,000
Amortisation -1.3 M -975,000 -460,000 -107,000 -13,000
EBIT -20.636 M -21.368 M -24.783 M -27.56 M -27.898 M
Pre Tax Profit -20.667 M -21.329 M -24.412 M -27.132 M -27.531 M
Tax Expense -39,000 -48,000 -51,000 -42,000 -40,000
Net Profit After Tax -20.706 M -21.377 M -24.463 M -27.174 M -27.571 M
Minority Interest 0 0 0 0 0
Preference Dividend 0 0 0 0 0
Net Abnormal Items 0 0 467,000 0 0
Reported Net Profit After Abnormal Items -20.706 M -21.377 M -24.123 M -27.174 M -27.571 M
Ending Shares 1.492 B 1.002 B 398.034 M 397.185 M 393.551 M
Weighted Average Shares 1.202 B 595.167 M 397.432 M 395.139 M 392.685 M
EPS After Abnormal Items (cents) -1.72 -3.59 -6.07 -6.88 -7.02
Breakdown 30/06/2021 30/06/2020 30/06/2019 30/06/2018 30/06/2017
Total Current Assets 25.65 M 25.45 M 16.973 M 37.8 M 61.255 M
Total Non Current Assets 8.555 M 7.614 M 5.608 M 3.967 M 3.088 M
Total Assets 34.205 M 33.064 M 22.581 M 41.767 M 64.343 M
Total Current Liabilities 8.134 M 5.109 M 6.661 M 5.663 M 5.469 M
Total Non Current Liabilities 557,000 594,000 135,000 102,000 77,000
Total Liabilities 8.691 M 5.703 M 6.796 M 5.765 M 5.546 M
Net Assets 25.514 M 27.361 M 15.785 M 36.002 M 58.797 M
Breakdown 30/06/2021 30/06/2020 30/06/2019 30/06/2018 30/06/2017
Net Operating Cash -13.258 M -19.218 M -19.588 M -23.458 M -25.566 M
Net Invested Cash -2.457 M -2.161 M -1.765 M -1.215 M -362,000
Net Financing Cash Flows 16.466 M 30.159 M 145,000 256,000 720,000
Beginning Cash 19.663 M 11.33 M 31.345 M 54.884 M 82.254 M
End Cash Position 19.681 M 19.663 M 11.33 M 31.345 M 54.884 M
Exchange Rate Adjustments -733,000 -447,000 1.193 M 878,000 -2.162 M
Other Cash Adjustments 0 0 0 0 0
Ending Cash 19.681 M 19.663 M 11.33 M 31.345 M 54.884 M

© Morningstar, Inc. 2021. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the market indices, commodities and regulatory news headlines, and other data or content contained herein to be accurate, complete, or timely, and nor shall they have any liability for its use or distribution. The data contained herein: (1) is proprietary to Morningstar and/or its affiliates (collectively, “Morningstar”) and/or their content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Our publications, ratings and products should be viewed as an additional investment resource, and not as your sole source of information. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your financial situation, contact a professional financial adviser. Some material is copyrighted and published under licence from ASX Operations Pty. Ltd. ACN 004523782.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK